1. the goal of treatment for SLE should be remission of systemic symptoms and organ manifestations or, if remission is not achieved, maintenance of minimum disease activity; remission or disease activity is determined by confirmatory lupus activity indices and/or organ-specific markers; 2. prevention of SLE relapses (especially severe relapses) is a practical goal and should be a therapeutic objective; 3. for asymptomatic patients, escalation of therapy based solely on stable or sustained serologic activity is not recommended; 4. In addition to controlling disease activity and preventing damage, factors that have a negative impact on health-related quality of life, such as fatigue, pain, and depression, should also be addressed; 6. 7. To achieve the desired goal, immunosuppressive therapy is recommended to maintain LN for at least 3 years after induction therapy; 8. Maintenance therapy for SLE should aim at the lowest dose of glucocorticoids that can control the disease, and if possible, glucocorticoids should be completely discontinued; 9. Prevention and treatment of diseases associated with antiphospholipid syndrome are also treatment goals for SLE, and treatment recommendations are the same as for primary The treatment recommendations are the same as those for primary antiphospholipid syndrome; 10. The use of antimalarials should be emphasized regardless of the use of other drugs; 11. To control the complications of lupus, immunomodulatory related treatments should be considered. All of the above have high clinical evidence, recommendation levels and recognition scores. The importance of maintenance therapy with immunosuppressants and glucocorticoids after LN-induced remission is particularly noted, as well as the principles of management of antiphospholipid syndrome and the importance of antimalarials. In conclusion, as a disease that is not yet curable, the treatment goals of SLE treatment strategies should include induction of remission, prevention of relapse, minimization of organ damage, long-term maintenance of disease stability, and control of complications. It is particularly important to consider individualized treatment plans for different patients.